SAN FRANCISCO, Feb. 3, 2016 /PRNewswire/ -- Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced today the pricing of an underwritten public offering of 2,000,000 shares of its common stock at an offering price to the public of $2.50 per share. All of the common stock is being offered by Jaguar Animal Health, Inc. The gross proceeds to Jaguar Animal Health, Inc. from this offering are expected to be approximately $5,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Jaguar Animal Health, Inc. has granted the underwriters a 45-day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on February 8, 2016, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and declared effective on February 3, 2016.
This offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, via telephone: 212-813-1010, or via e-mail: [email protected] Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses. Canalevia™ is Jaguar's lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Canalevia™ is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company's lead non-drug products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, and formulations of Canalevia™ for cats, horses and dogs.
Certain statements in this press release, including those relating to the public offering, the expected gross proceeds and the expected closing of the offering, constitute "forward-looking statements." The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Forward-looking statements may be identified by words such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
SOURCE Jaguar Animal Health, Inc.